TAIPEI, Aug. 28, 2025 /PRNewswire/ — Foresee Pharmaceuticals (6576.TWO), (“Foresee”) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for CAMCEVI ETM (leuprolide mesylate 21 mg, ready-to-use […]
Tag: Foresee Pharmaceuticals Co.
Foresee Pharmaceuticals Announces First Patient Dosed in the Phase 2 WINDWARD Study of the ALDH2 Activator Mirivadelgat for Patients with Pulmonary Hypertension-Associated Interstitial Lung Disease (PH-ILD)
The WINDWARD study is a multinational, double-blind, 3-arm Phase 2 study to evaluate the safety and efficacy of mirivadelgat in adult subjects with PH-ILD. Mirivadelgat is a first-in-class oral small molecule with a novel mechanism […]
Foresee Pharmaceuticals Receives the Third Positive Recommendation from the DSMB to Continue the Casppian Study
The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of patient enrollment as planned. There has been no safety concern with the use of leuprolide (FP-001) injectable Emulsion in pediatric CPP patients. TAIPEI, […]
Foresee Pharmaceuticals Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer
TAIPEI, Oct. 29, 2024 /PRNewswire/ — Foresee Pharmaceuticals Co., Ltd. (TPEx: 6576), (“Foresee”) announced today that it has submitted a 505(b)(2) New Drug Application for the 3-month version of CAMCEVI, a ready-to-use 3-month depot formulation […]
Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Selective MMP-12 Inhibitor.
TAIPEI, Oct. 20, 2024 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical study in Australia with linvemastat (FP-020), its novel, […]
